21.54
전일 마감가:
$21.48
열려 있는:
$21.37
하루 거래량:
50,806
Relative Volume:
0.38
시가총액:
$226.57M
수익:
$56.54M
순이익/손실:
$-30.70M
주가수익비율:
-55.23
EPS:
-0.39
순현금흐름:
$-31.05M
1주 성능:
+10.80%
1개월 성능:
-2.22%
6개월 성능:
+70.95%
1년 성능:
+65.69%
Cidara Therapeutics Inc Stock (CDTX) Company Profile
명칭
Cidara Therapeutics Inc
전화
858-752-6170
주소
6310 NANCY RIDGE DRIVE, SAN DIEGO, CA
CDTX을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
CDTX
Cidara Therapeutics Inc
|
21.54 | 226.57M | 56.54M | -30.70M | -31.05M | -0.39 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Cidara Therapeutics Inc Stock (CDTX) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-03-12 | 개시 | Citizens JMP | Mkt Outperform |
2025-01-27 | 재개 | Cantor Fitzgerald | Overweight |
2024-12-13 | 개시 | RBC Capital Mkts | Outperform |
2024-11-08 | 개시 | Guggenheim | Buy |
2024-08-14 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
2021-12-03 | 재개 | H.C. Wainwright | Buy |
2021-09-22 | 업그레이드 | WBB Securities | Buy → Strong Buy |
2021-03-04 | 개시 | Aegis Capital | Buy |
2019-09-04 | 업그레이드 | Wedbush | Neutral → Outperform |
2018-07-26 | 개시 | Citigroup | Buy |
2017-04-21 | 개시 | Raymond James | Strong Buy |
2017-04-17 | 재확인 | H.C. Wainwright | Buy |
2017-04-12 | 개시 | Ladenburg Thalmann | Buy |
2017-04-11 | 재개 | Wedbush | Outperform |
2017-02-22 | 재확인 | H.C. Wainwright | Buy |
2017-02-22 | 업그레이드 | WBB Securities | Sell → Hold |
2016-12-21 | 재개 | Leerink Partners | Outperform |
2016-12-19 | 개시 | H.C. Wainwright | Buy |
2016-09-23 | 다운그레이드 | WBB Securities | Hold → Sell |
2015-10-09 | 업그레이드 | WBB Securities | Sell → Hold |
2015-05-11 | 개시 | Jefferies | Buy |
2015-05-11 | 개시 | Leerink Partners | Outperform |
2015-05-11 | 개시 | Needham | Buy |
2015-05-11 | 개시 | Wedbush | Outperform |
2015-04-23 | 개시 | WBB Securities | Sell |
모두보기
Cidara Therapeutics Inc 주식(CDTX)의 최신 뉴스
Cidara Therapeutics to Report First Quarter 2025 Financial Results on May 8, 2025 - Nasdaq
Cidara Therapeutics to Report First Quarter 2025 Financial - GlobeNewswire
(CDTX) Trading Signals - news.stocktradersdaily.com
Cidara Therapeutics (NASDAQ:CDTX) Upgraded to “Sell” at StockNews.com - Defense World
Needham & Company LLC Reaffirms “Buy” Rating for Cidara Therapeutics (NASDAQ:CDTX) - Defense World
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Receives Average Rating of “Buy” from Analysts - Defense World
Cidara Therapeutics (NASDAQ:CDTX) Upgraded by StockNews.com to Sell Rating - Defense World
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Sees Significant Increase in Short Interest - Defense World
Cidara Therapeutics (NASDAQ:CDTX) Shares Pass Above 50 Day Moving Average – Time to Sell? - Defense World
Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - GlobeNewswire
New Executive Joins Cidara Therapeutics with $580K+ Stock Compensation Package - Stock Titan
Cidara Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference - GlobeNewswire
Cidara Therapeutics Unveils Latest Innovations at Elite Needham Healthcare Conference - Stock Titan
(CDTX) Investment Analysis - news.stocktradersdaily.com
Elicio Therapeutics Hires CFO From Cidara Therapeutics - MarketWatch
Elicio Therapeutics Appoints Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer - GlobeNewswire
Wall Street Analysts Predict a 64.5% Upside in Cidara Therapeutics (CDTX): Here's What You Should Know - MSN
Cidara Therapeutics to Participate in World Health - GlobeNewswire
Cidara Therapeutics to present on CD388 at ICAR 2025 - Yahoo Finance
Cidara's Breakthrough H5N1 Flu Drug Takes Center Stage at WHO Emergency Preparedness Meeting - StockTitan
Short Interest in Cidara Therapeutics, Inc. (NASDAQ:CDTX) Increases By 30.7% - Defense World
Cidara Therapeutics Announces Two Presentations on CD388 in Influenza at International Conference on Antiviral Research (ICAR) 2025 - The Manila Times
Cidara Therapeutics Announces Two Presentations on CD388 in - GlobeNewswire
Major Milestone: Cidara's Novel Flu Prevention Drug Completes Massive 5,000-Patient Trial - StockTitan
Cidara Therapeutics Announces Publication of CD388 Preclinical Data in Nature Microbiology - GlobeNewswire
Revolutionary Universal Flu Drug Shows Promise Against All Strains, Including Bird Flu - StockTitan
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Receives $39.14 Average Target Price from Analysts - Defense World
(CDTX) Long Term Investment Analysis - Stock Traders Daily
Citizens Jmp Begins Coverage on Cidara Therapeutics (NASDAQ:CDTX) - Defense World
Cidara therapeutics COO Shane Ward sells shares worth $36,542 By Investing.com - Investing.com Australia
Cidara therapeutics chief scientific officer sells shares worth $38,939 By Investing.com - Investing.com Australia
Cidara therapeutics COO Shane Ward sells shares worth $36,542 - Investing.com India
Cidara therapeutics chief scientific officer sells shares worth $38,939 - Investing.com India
Cidara Therapeutics Executives Sell Shares to Cover Tax Obligations - TradingView
HC Wainwright Issues Negative Estimate for CDTX Earnings - Defense World
Citizens Capital Markets Initiates Coverage of Cidara Therapeutics (CDTX) with Market Outperform Recommendation - Nasdaq
Cidara stock gains on Citizens' bullish view (CDTX:NASDAQ) - Seeking Alpha
Cidara Therapeutics initiated with an Outperform at Citizens JMP - TipRanks
Cidara stock gains on JMP analyst’s upbeat outlook By Investing.com - Investing.com Canada
FY2029 Earnings Forecast for CDTX Issued By HC Wainwright - Defense World
Buy Rating for Cidara Therapeutics: Promising Potential of CD388 in Influenza Prevention - TipRanks
HC Wainwright Issues Positive Forecast for Cidara Therapeutics (NASDAQ:CDTX) Stock Price - Defense World
Cidara stock price target raised to $35 at H.C. Wainwright By Investing.com - Investing.com Canada
Cidara Therapeutics price target raised to $35 from $24 at H.C. Wainwright - TipRanks
Ed Arce’s Buy Rating for Cidara Therapeutics Driven by Accelerated CD388 Program and Promising Phase 2b NAVIGATE Study Developments - TipRanks
Head-To-Head Analysis: Cidara Therapeutics (NASDAQ:CDTX) vs. Neumora Therapeutics (NASDAQ:NMRA) - Defense World
Cidara Therapeutics Inc (CDTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):